Dave Jorgensen
@djorgensen.bsky.social
Dad of 3, Geospatial Analyst, looking for a cure for Duchenne Muscular Dystrophy.
FDA Grants Approval to DUVYZAT™ (Givinostat) for Duchenne Muscular Dystrophy.
FDA Grants Approval to DUVYZAT™ (Givinostat)
PPMD is excited to learn that the FDA has granted approval to DUVYZAT™ (givinostat), a histone deacetylase (HDAC) inhibitor indicated for individuals diagnosed with Duchenne muscular dystrophy from si...
www.parentprojectmd.org
March 22, 2024 at 1:55 AM
FDA Grants Approval to DUVYZAT™ (Givinostat) for Duchenne Muscular Dystrophy.
Wave Life Sciences has fully enrolled and started dosing WVE-N531 exon-skipping drug for #Duchenne ir.wavelifesciences.com/news-release...
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenn...
The Investor Relations website contains information about Wave Life Sciences's business for stockholders, potential investors, and financial analysts.
ir.wavelifesciences.com
December 17, 2023 at 5:34 AM
Wave Life Sciences has fully enrolled and started dosing WVE-N531 exon-skipping drug for #Duchenne ir.wavelifesciences.com/news-release...
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candid...
The Investor Relations website contains information about Solid Biosciences Inc.'s business for stockholders, potential investors, and financial analysts.
investors.solidbio.com
November 14, 2023 at 9:54 PM
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Maverick was a very good remake
October 20, 2023 at 3:24 AM
Maverick was a very good remake
WVE-N531 yields 53% mean exon 53 skipping in skeletal muscle of boys with Duchenne muscular dystrophy (DMD) after three biweekly doses
P22 WVE-N531 yields 53% mean exon 53 skipping in skeletal muscle of boys with Duchenne muscular dyst...
WVE-N531 is an investigational stereopure antisense oligonucleotide being developed as a potential therapy for patients with DMD amenable to exon 53 s…
www.sciencedirect.com
October 8, 2023 at 7:44 PM
WVE-N531 yields 53% mean exon 53 skipping in skeletal muscle of boys with Duchenne muscular dystrophy (DMD) after three biweekly doses